Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Depreciation & Amortization (CF): 2016-2025

Historic Depreciation & Amortization (CF) for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $1.0 million.

  • Collegium Pharmaceutical's Depreciation & Amortization (CF) rose 9.20% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 14.24%. This contributed to the annual value of $3.9 million for FY2024, which is 10.30% up from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Depreciation & Amortization (CF) stood at $1.0 million, which was down 8.99% from $1.1 million recorded in Q2 2025.
  • Collegium Pharmaceutical's Depreciation & Amortization (CF)'s 5-year high stood at $1.1 million during Q2 2025, with a 5-year trough of $424,000 in Q4 2021.
  • In the last 3 years, Collegium Pharmaceutical's Depreciation & Amortization (CF) had a median value of $949,000 in 2023 and averaged $964,636.
  • Data for Collegium Pharmaceutical's Depreciation & Amortization (CF) shows a peak YoY spiked of 129.74% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Collegium Pharmaceutical's Depreciation & Amortization (CF) stood at $424,000 in 2021, then soared by 94.58% to $825,000 in 2022, then increased by 15.03% to $949,000 in 2023, then climbed by 9.69% to $1.0 million in 2024, then increased by 9.20% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, $1.1 million for Q2 2025, and $1.1 million during Q1 2025.